Wedbush Starts Pharmacyclics (PCYC) at Outperform

December 21, 2009 1:02 PM EST Send to a Friend
Get Alerts PCYC Hot Sheet
Price: $132.82 +1.04%

Rating Summary:
    15 Buy, 9 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 9 | Down: 10 | New: 35
Trade PCYC Now!
Join SI Premium – FREE
Wedbush initiates coverage on Pharmacyclics (Nasdaq: PCYC) with an Outperform rating and a $5.50 fair value estimate.

The firm feels that "the Street is not fully accounting for PCYC's BTK inhibitor potential in the CLL/SLL setting, let alone for its follow-on opportunity autoimmune/inflammatory diseases, and continued positive data from the ongoing Phase I NHL setting could drive interest in the company and the stock."

Wedbush said it got its $5.50 fair value estimate based on 7x the firm's CY16 sales projection for PCI-32765, discounting back the product 7 years at 30%.

Visit our Analyst Ratings page to see all the analyst action on shares of Pharmacyclics.

Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on developing and commercializing small-molecule drugs for the treatment of immune mediated disease and cancer.

You May Also Be Interested In





Related Categories

New Coverage

Add Your Comment